Clinical Study Of Pioglitazone For Treatment Of Polycystic Ovary Syndrome

Background and objective:Polycystic ovary syndrome(PCOS) is a genitalis endocrine disturbance disease which is common in women of reproductive age. Recent studies have demonstrated that insulin resistance and hyperinsulinism play a key role in the pathogenesis of polycystic ovary syndrome. It causes hyperandrogenisrn and high luteinizing hormone, amenorrhea and infertility. On the other hand, it causes the glycolipids metabolism disturbance and the metabolism complication, such as diabetes mellitus(DM), coronary heart disease(CHD), hypertension. Therefore the treatment of improving insulin sensitivity has opened a new therapeutic perspective as to polycystic ovary syndrome.Pioglitazone is one of the insulin-sensitizing compounds, thiazolidinediones (TZDs)and it is a ligand for pemxisome proliferators activated receptor gamma (PPARgamma) . Pioglitazone was given to the patients with PCOS in this investigation. Before and after treatment, BMI, WHR, blood pressure, blood sugar, insulin, TG, TC, HDL, LDL, sex hormone, ovulation rate, liver and renal function were determined and compared. The aim is to observe the action of pioglitazone on the insulin resistance and sex hormones disturbance of polycystic ovary syndrome. Methods:...